Date: 2016-12-14
Type of information: Licensing agreement
Compound: GPCR BioSens-All™ technology
Company: Domain Therapeutics (France) Alkermes (Ireland)
Therapeutic area: CNS diseases
Type agreement: licensing
Action mechanism: BioSens-All™ is a GPCR biosensor technology was originally developed by a team of researchers led by Prof. Michel Bouvier from the Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal, including Prof. Graciela Pineyro at the Ste-Justine Hospital research center, Dr. Christian Le Gouill at the Université de Montréal, Prof. Terry Hebert and Prof. Stéphane Laporte at McGill University, and Prof. Richard Leduc at Sherbrooke University. Domain Therapeutics acquired exclusive commercialization rights to the technology through two licensing agreements signed in 2013 and 2016.
G protein-coupled receptors (GPCRs) constitute one of the main classes of therapeutic targets for many indications of the central nervous system, metabolic disorders and cardiovascular, respiratory, urinary or gastrointestinal diseases and more recently cancer. The binding of a hormone or a specific ligand to a receptor’s binding site activates one or several pathways for intracellular signalling, which enables the cell to provide an adapted response to the change in its environment. BioSens-All™ technology allows the understanding of
signalling pathways activated by each candidate molecule, thus predicting its pharmacological profile. This approach makes it possible at a very early stage to choose the molecules that have the potential of being active without presenting side effects or inducing tolerance to treatment.
BioSens-All™ can monitor several dozen signaling pathways, in living cells, in parallel assays and in a homogeneous format. This allows the link to be made between specific signaling signatures of drug candidates and their biological effects. The BioSens-All™ technology generates and analyzes comprehensive signaling data on GPCR drug candidates, potentially accelerating the discovery and development of biased drugs.
Disease:
Details: * On December 14, 2016, Domain Therapeutics announced the signing of a licensing agreement for its GPCR
BioSens-All™ technology with Alkermes. Alkermes is entitled to use BioSens-All™ as part of its drug discovery efforts. No financial details have been disclosed.
Financial terms:
Latest news:
